News

New drug for Parkinson’s shown to be effective in clinical trials: 'Very encouraged'
A new pill, tavapadon, has shown potential in easing Parkinson’s symptoms while limiting side effects. In patients taking at ...
Hikma acquires rights to generic version of Novartis' Mekinist
Hikma buys rights to FDA-approved cancer treatment trametinib, a generic version of Novartis' (NVS) Mekinist, with 180 days ...
ALS News Today2d
Brainstorm seeking FDA’s OK to launch NurOwn Phase 3b trial
Brainstorm Cell Therapeutics is seeking FDA clearances to launch a Phase 3b clinical trial to test its NurOwn stem cell ...
Alembic Pharmaceuticals receives USFDA approval for Carbamazepine Tablets
Alembic Pharmaceuticals (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carbamazepine Tablets USP ...
Alembic Pharma receives final approval for Carbamazepine tablets
Alembic Pharmaceuticals announced that it has received final approval from the U.S. Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Carbamazepine Tablets USP, ...
Physicians Committee for Responsible Medicine3d
FDA’s Plan to Replace Animal Testing Begins a ‘New Era for Drug Testing,’ says Doctors Group
The nonprofit Physicians Committee for Responsible Medicine, which promotes the use of human-relevant test methods to replace animal use in drug testing and development, enthusiastically supports the ...
Alberta tables new law for mandatory treatment for drug addicts
NP TALKS: Election 2025: Canadian unity in crisis. Join the live discussion on April 24 at 3 p.m. ET.
CURE5d
Ziftomenib Submits New Drug Application to FDA for R/R NPM1-Mutant AML
The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.
Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...